Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis (NTLC75-ITA)

15 september 2026 bijgewerkt door: Ognjen Barčot, MD, PhD, University Hospital of Split

Relative Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis After Right Colectomy: A Prospective Observational Pilot Study

This prospective single-center pilot cohort will include 40 consecutive adults undergoing elective right colectomy with a Barcelona ileotransverse anastomosis using an NTLC75/SR75 linear stapler. A sensor mounted externally on the stapler handle will record relative mechanical signals during two calibration closures without firing and two standard stapler activations. The main objectives are to obtain at least 35 technically valid final cross-stapling recordings and to estimate the association between the normalized final maximum signal and C-reactive protein on postoperative day 3. Clinical treatment is unchanged and follow-up continues through postoperative day 90.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

Two close-only calibration measurements will be recorded once on double-walled small bowel and colon located on the resection-specimen side, outside the tumor and resection margins, with the anvil toward the mesentery, without firing or consuming additional reloads. The first standard activation forms the ileotransverse anastomotic channel without cross-stapling, with the anvil in the colon and reload jaw in the small bowel. The final closure is oriented with the device tip toward the small bowel so that knife travel proceeds from colon to small bowel and crosses two existing staple lines. The surgeon measures flattened tissue lengths and both cross-stapling distances with a sterile ruler to the nearest whole millimeter. Raw signals are preserved; forward and return branches are resampled to 200 normalized-time points. The signal is not calibrated as absolute force, is not shown to the surgeon and does not influence care. Other curve features and clinical outcomes are exploratory.

Studietype

Observationeel

Inschrijving (Geschat)

40

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Split, Kroatië, 21000
        • University Hospital of Split, Department of Surgery
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adults scheduled for elective right colectomy for operable right-sided colon cancer with planned primary Barcelona ileotransverse anastomosis using NTLC75/SR75.

Beschrijving

Inclusion Criteria:

  • Age 18 years or older
  • Elective right colectomy for histologically confirmed or clinically or radiologically suspected operable right-sided colon cancer
  • Planned primary Barcelona ileotransverse anastomosis using NTLC75/SR75
  • Capacity to understand the study and provide written informed consent

Exclusion Criteria:

  • Emergency surgery
  • No planned or performed primary anastomosis
  • Another anastomotic technique or stapler model
  • Withdrawal or inability to consent
  • Intraoperative change of plan preventing the planned measurement procedure

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Elective Right Colectomy Cohort

Adults undergoing elective right colectomy with a Barcelona ileotransverse anastomosis using NTLC75/SR75 as standard clinical care. Relative mechanical signals are recorded passively during two close-only calibration closures without firing and two standard stapler activations.

An external DF9-40 sensor mounted on the NTLC75 handle passively records relative mechanical signals. One close-only calibration recording is obtained on double-walled small bowel and one on double-walled colon on the resection-specimen side, outside the tumor and resection margins, with the anvil toward the mesentery, without firing. Signals are also recorded during standard ITA channel formation (anvil in colon; reload jaw in small bowel; no cross-stapling) and final closure (tip toward small bowel; knife travel from colon to small bowel across two existing staple lines). The signal is not shown to the surgeon and does not affect clinical care.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Participants With a Technically Valid Final Cross-Stapling Signal Record
Tijdsspanne: Intraoperative, during the final cross-stapling activation

Number and percentage of all 40 enrolled participants with a complete and technically valid final cross-stapling signal record. A valid record includes a complete forward branch, an identifiable reference return branch, no peak-obscuring saturation, no loss of sensor contact, and successful application of the locked signal-processing algorithm. Missing or invalid records remain in the denominator. Prespecified feasibility target: at least 35 of 40 participants.

Intraoperative, during the final cross-stapling activation
C-Reactive Protein Concentration on Postoperative Day 3 in Relation to the Normalized Final Maximum Signal
Tijdsspanne: Postoperative day 3

Routine-care serum C-reactive protein in mg/L, analyzed continuously in association with the normalized maximum amplitude of the final cross-stapling forward branch using a scatterplot, Pearson or Spearman correlation, and simple linear regression.

Postoperative day 3

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CloseMax During Small-Bowel Close-Only Calibration
Tijdsspanne: Intraoperative, during the small-bowel close-only calibration

Maximum baseline-corrected relative signal amplitude during complete stapler closure on the double-walled small bowel located on the resection-specimen side, without firing. Reported in relative signal units.

Intraoperative, during the small-bowel close-only calibration
Maximum Signal Amplitude During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Maximum baseline-corrected amplitude of each forward and return signal branch, calculated separately for the ileotransverse anastomotic-channel and final cross-stapling activations. Reported in relative signal units.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Inter-Rater Agreement for Manual Curve Classification
Tijdsspanne: Through study completion and before database lock, an anticipated 16 months

Two independent raters blinded to C-reactive protein values and clinical outcomes classify technical validity, curve morphology, sticking, and irregularity for the ileotransverse anastomotic-channel and final cross-stapling recordings. Agreement between the two initial categorical ratings is quantified using Cohen's kappa before consensus resolution.

Through study completion and before database lock, an anticipated 16 months
C-Reactive Protein Concentration
Tijdsspanne: Postoperative days 1 and 3

Routine-care serum C-reactive protein concentration recorded separately on postoperative days 1 and 3 and reported in mg/L. The prespecified association between postoperative-day-3 CRP and the normalized final cross-stapling maximum remains the second primary outcome.

Postoperative days 1 and 3
Highest Clavien-Dindo Complication Grade
Tijdsspanne: From the index operation through postoperative day 90

Highest Clavien-Dindo grade assigned to any postoperative complication experienced by each participant through postoperative day 90. Participants without a complication are recorded as having no Clavien-Dindo complication.

From the index operation through postoperative day 90
Participants With Anastomosis-Related Events
Tijdsspanne: From the index operation through postoperative day 90

Number and percentage of participants with anastomotic leak, anastomotic bleeding, perianastomotic collection or abscess, anastomosis-related radiologic or endoscopic intervention, reoperation, or surgical revision. Each event type is reported separately.

From the index operation through postoperative day 90
Length of Postoperative Hospital Stay
Tijdsspanne: From the index operation to discharge from the index hospitalization, assessed through postoperative day 90

Number of calendar days from the index operation to discharge from the index hospitalization.

From the index operation to discharge from the index hospitalization, assessed through postoperative day 90
CloseMax During Colon Close-Only Calibration
Tijdsspanne: Intraoperative, during the colon close-only calibration

Maximum baseline-corrected relative signal amplitude during complete stapler closure on the double-walled colon located on the resection-specimen side, without firing. Reported in relative signal units.

Intraoperative, during the colon close-only calibration
CloseMax During Ileotransverse Anastomotic Channel Formation
Tijdsspanne: Intraoperative, during the stapler activation forming the ileotransverse anastomotic channel

Maximum baseline-corrected relative signal amplitude during the closing phase preceding the standard stapler activation used to form the ileotransverse anastomotic channel without cross-stapling. Reported in relative signal units.

Intraoperative, during the stapler activation forming the ileotransverse anastomotic channel
CloseMax During Final Cross-Stapling
Tijdsspanne: Intraoperative, during the final cross-stapling activation

Maximum baseline-corrected relative signal amplitude during the closing phase preceding the final cross-stapling activation. Reported in relative signal units.

Intraoperative, during the final cross-stapling activation
Normalized Time to Maximum Signal Amplitude
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Position of the maximum baseline-corrected amplitude within each signal branch, expressed as a percentage of that branch's total duration from 0% to 100%. Calculated separately for the forward and return branches of both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal-Branch Duration During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Actual elapsed duration of each forward and return signal branch, calculated separately for the ileotransverse anastomotic-channel and final cross-stapling activations. Reported in seconds from the preserved raw timestamps.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal Peak Count During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Number of signal peaks identified by the locked signal-processing algorithm in each 200-point normalized-time branch. Calculated separately for the forward and return branches of both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Maximum Signal Slope During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Maximum positive slope of each 200-point normalized-time signal branch, calculated using the locked signal-processing algorithm. Reported in relative signal units per normalized-time point and calculated separately for both activations.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Area Under the Signal Curve During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Area under each baseline-corrected 200-point normalized-time signal branch, calculated separately for the forward and return branches of both activations. Reported in relative signal units multiplied by normalized time.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Signal Amplitude Variability During ITA and Final Cross-Stapling Activations
Tijdsspanne: Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations

Standard deviation of the baseline-corrected amplitudes across each 200-point normalized-time signal branch. Calculated separately for the forward and return branches of both activations and reported in relative signal units.

Intraoperative, during the ileotransverse anastomotic-channel and final cross-stapling activations
Leukocyte Count
Tijdsspanne: Postoperative days 1 and 3

Routine-care peripheral blood leukocyte count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Neutrophil Count
Tijdsspanne: Postoperative days 1 and 3

Routine-care peripheral blood absolute neutrophil count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Lymphocyte Count
Tijdsspanne: Postoperative days 1 and 3

Routine-care peripheral blood absolute lymphocyte count recorded separately on postoperative days 1 and 3 and reported as ×10^9/L.

Postoperative days 1 and 3
Neutrophil-to-Lymphocyte Ratio
Tijdsspanne: Postoperative days 1 and 3

Neutrophil-to-lymphocyte ratio calculated from the absolute neutrophil and lymphocyte counts obtained on the same postoperative day. Recorded separately on postoperative days 1 and 3 and reported as a unitless ratio.

Postoperative days 1 and 3
Serum Albumin Concentration
Tijdsspanne: Postoperative days 1 and 3

Routine-care serum albumin concentration recorded separately on postoperative days 1 and 3 and reported in g/L.

Postoperative days 1 and 3
Serum Creatinine Concentration
Tijdsspanne: Postoperative days 1 and 3

Routine-care serum creatinine concentration recorded separately on postoperative days 1 and 3 and reported in µmol/L.

Postoperative days 1 and 3
Estimated Glomerular Filtration Rate
Tijdsspanne: Postoperative days 1 and 3

Laboratory-reported estimated glomerular filtration rate recorded separately on postoperative days 1 and 3 and reported in mL/min/1.73 m².

Postoperative days 1 and 3
Participants With a Major Postoperative Complication
Tijdsspanne: From the index operation through postoperative day 90

Number and percentage of participants experiencing at least one major postoperative complication, defined as Clavien-Dindo grade III, IV, or V.

From the index operation through postoperative day 90
Comprehensive Complication Index Score
Tijdsspanne: From the index operation through postoperative day 90

Comprehensive Complication Index score calculated from all postoperative complications experienced by each participant through postoperative day 90. Reported on the standard continuous scale from 0, indicating no complication, to 100, indicating death.

From the index operation through postoperative day 90
Participants With All-Cause Readmission Within 30 Days
Tijdsspanne: From discharge after the index hospitalization through postoperative day 30

Number and percentage of participants with at least one unplanned all-cause hospital readmission by postoperative day 30.

From discharge after the index hospitalization through postoperative day 30
Participants Undergoing Reoperation Within 30 Days
Tijdsspanne: From the index operation through postoperative day 30

Number and percentage of participants undergoing at least one unplanned surgical reoperation for any cause by postoperative day 30.

From the index operation through postoperative day 30
All-Cause Mortality Within 30 Days
Tijdsspanne: From the index operation through postoperative day 30

Number and percentage of participants who die from any cause by postoperative day 30.

From the index operation through postoperative day 30
All-Cause Mortality Within 90 Days
Tijdsspanne: From the index operation through postoperative day 90

Number and percentage of participants who die from any cause by postoperative day 90.

From the index operation through postoperative day 90

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

3 november 2027

Studie voltooiing (Geschat)

29 januari 2028

Studieregistratiedata

Eerst ingediend

8 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

15 september 2026

Eerst geplaatst (Werkelijk)

22 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 september 2026

Laatste update ingediend die voldeed aan QC-criteria

15 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Patient-level data will not be made public because the small single-center surgical cohort carries a material re-identification risk.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren